Investigating a new treatment target for a common childhood brain tumor
B7-H3 in Medulloblastoma: evaluating its expression and function to harness new therapeutic targets
This study is looking at a molecule called B7-H3 to see if blocking it can help improve treatment for children with medulloblastoma, a common type of brain tumor, especially for those who haven't had success with current therapies.
Quick facts
| Grant type | Career grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Albert Einstein College of Medicine NIH-funded |
| Lab location | 1 site (Bronx, United States) |
| Project ID | NIH-10817027 on NIH RePORTER |
What this research studies
This research focuses on understanding the role of a specific immune checkpoint molecule, B7-H3, in medulloblastoma, the most prevalent malignant brain tumor in children. The project aims to evaluate how B7-H3 can be targeted with blocking antibodies to improve treatment outcomes for pediatric patients, particularly those whose tumors do not respond to existing therapies. By using both animal models and human cell lines, the research seeks to establish a foundation for future clinical trials that could lead to new therapeutic options for affected children.
Who could benefit from this research
Good fit: Ideal candidates for this research are children diagnosed with medulloblastoma, particularly those who have not responded to standard treatments.
Not a fit: Patients with other types of brain tumors or those whose medulloblastoma is already effectively treated may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new, effective treatments for children with medulloblastoma, especially those with resistant tumors.
How similar studies have performed: While previous studies have explored immune checkpoint molecules in cancer treatment, the specific focus on B7-H3 in medulloblastoma represents a novel approach.
Where this research is happening
Bronx, United States
- Albert Einstein College of Medicine — Bronx, United States (Active)
Researchers
- Principal investigator: Martin, Allison M. — Albert Einstein College of Medicine
- Study coordinator: Martin, Allison M.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.